|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 83.35 HKD | +4.19% |
|
+8.81% | +46.10% |
| 04-10 | Henlius Biotech Doses First Patient in Breast Cancer Drug Study | MT |
| 04-09 | Henlius Biotech Gets China Nod for Two New Indications of Lymphoma Drug | MT |
Main competitors
| Revenues (Y-1) | Net Margin (Y-1) | EBIT Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Y-1) | ||
|---|---|---|---|---|---|---|---|
| 784M | - | 15.05% | 31.52% | - | - | ||
| 14.34B | 31.41% | 34.05% | 16.13% | 12.48% | -1.09x | ||
| 9.09B | 20.13% | 25.95% | 14.03% | 6.99% | 0.16x | ||
| 3.95B | 31.29% | 39.94% | 17.59% | 11.33% | -0.18x | ||
| 15.56B | 19.3% | 28.72% | 16.36% | 7.75% | 1.74x | ||
| 9.89B | 13.07% | 28.69% | 7.39% | 4.5% | 0.68x | ||
| 1.94B | -145.16% | -158.13% | -28.87% | -21.31% | 2.03x | ||
| 1.29B | -1% | -8.02% | -0.74% | -0.45% | -11.4x | ||
| 5.14B | 25.03% | 31.43% | 31.7% | 22.02% | -1.81x | ||
| 3.06B | 1.69% | 28.34% | 14.97% | 0.67% | 0.88x | ||
| 502M | -144.39% | -104.25% | - | -78.14% | -2.48x | ||
| 150M | 66.87% | 49.52% | 39.67% | 13.78% | -0.5x | ||
| 3.22B | 10.83% | 12.71% | 5.94% | 4.79% | -1.97x | ||
| 638M | -28.69% | -26.12% | -252.11% | -29.11% | 0.85x | ||
| 389M | 52.64% | 41.45% | 18.91% | - | - | ||
| 164M | 59.03% | 60.87% | 13.47% | 11.81% | - | ||
| 1.25B | 22.95% | 28.06% | 14.19% | 8.74% | 0.28x | ||
| 308M | 4.73% | 4.18% | 0.85% | - | -5.29x | ||
| 8.83B | 5.34% | 18.49% | 6.14% | 2.42% | 4.83x | ||
| Average | 4.24B | 2.5% | 7.94% | -1.83% | -1.36% | -0.83x | |
| Weighted average by Cap. | 7.51B | 8.85% | 14.61% | 7.39% | 3.53% | -0.61x |
- Stock Market
- Equities
- 2696 Stock
- Sector Shanghai Henlius Biotech, Inc.
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















